In a recent visit to the FDA, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. reportedly discussed the existence of the “Deep State” and its influence on government agencies. Kennedy pointed to “institutional pressures” as a driving force behind the deep state, rather than individual figures like George Soros or Bill Gates. He also criticized the FDA for becoming a “sock puppet” of the industries it regulates, suggesting that this pattern is evident across all government agencies, not just the FDA.
One area where Kennedy has observed this regulatory capture is in the FDA’s Generally Recognized as Safe (GRAS) system, which he believes provides a loophole for food companies. In an effort to increase transparency and improve Americans’ health, Kennedy directed the FDA to reevaluate its policies on ingredient approvals for food products. By eliminating this loophole, Kennedy believes that consumers will have a better understanding of what they are consuming and will ultimately lead to better health outcomes.
Kennedy’s criticisms of the FDA are not new, as he has been vocal throughout the 2024 election cycle about the changes he believes are necessary to improve public health. Kennedy, who endorsed now-President Donald Trump, issued warnings to FDA employees to preserve their records and “pack their bags” if they were part of a corrupt system. Kennedy’s focus on improving public health extends beyond the FDA, as he recently embarked on a MAHA (Make America Healthy Again) tour to discuss various state laws related to nutrition in schools.
Despite Kennedy’s criticisms and calls for change within the FDA, it is unclear what specific actions he plans to take to address the issues he has identified. Kennedy has not shied away from expressing his disdain for the FDA and other government agencies, suggesting that significant reform is needed to ensure the health and well-being of Americans. As the head of the HHS, Kennedy has the authority to influence policy and regulation related to public health, making his perspective on the “Deep State” and regulatory capture within the FDA significant in shaping future initiatives.
